caffeic acid phenethyl ester has been researched along with stf 62247 in 1 studies
| Studies (caffeic acid phenethyl ester) | Trials (caffeic acid phenethyl ester) | Recent Studies (post-2010) (caffeic acid phenethyl ester) | Studies (stf 62247) | Trials (stf 62247) | Recent Studies (post-2010) (stf 62247) |
|---|---|---|---|---|---|
| 840 | 1 | 469 | 27 | 0 | 17 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiasson, A; Cormier, M; Dastous, S; Doiron, JA; Lyons, P; Selka, A; Surette, ME; Touaibia, M; Turcotte, S | 1 |
1 other study(ies) available for caffeic acid phenethyl ester and stf 62247
| Article | Year |
|---|---|
Discovery of a novel 2,5-dihydroxycinnamic acid-based 5-lipoxygenase inhibitor that induces apoptosis and may impair autophagic flux in RCC4 renal cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Carcinoma, Renal Cell; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HEK293 Cells; Humans; Kidney Neoplasms; Lipoxygenase Inhibitors; Molecular Structure; Neutrophils; Structure-Activity Relationship | 2019 |